Boryung Launches "Kanavjet," a Treatment for Hypertension and Dyslipidemia
Triple Combination Drug for Hypertension and Dyslipidemia Based on Kanarb
Boryung announced on May 28 that it will launch "Kanavjet," a triple-combination drug for hypertension and dyslipidemia, on June 1. Kanavjet is a combination drug that merges the Korean-developed antihypertensive agent "Kanarb" (fimasartan) with atorvastatin and ezetimibe.
The launch symposium of Boryung's triple-combination drug for hypertension and dyslipidemia, 'Kanabjet,' held on the 21st. Boryung
View original imageKanavjet is a product that combines fimasartan, an angiotensin II receptor blocker (ARB), with atorvastatin, a statin, and ezetimibe, a cholesterol absorption inhibitor. It is mainly prescribed for patients with both hypertension and dyslipidemia, as well as high-risk patients who have not reached their LDL cholesterol targets with statin monotherapy alone.
Boryung explained that the launch reflects the current prescribing trend emphasizing integrated management of chronic diseases and early combination therapy. The company also pointed out that approximately 72% of hypertension patients in Korea also have dyslipidemia.
Boryung held a symposium on May 21 to commemorate the launch of Kanavjet, where it introduced treatment strategies for managing both hypertension and dyslipidemia, as well as ways to utilize combination drugs.
Professor Lee Chanju from the Department of Cardiology, Yonsei University College of Medicine, stated, "Fimasartan is an ingredient whose safety and efficacy have been confirmed in various patient groups, based on its high receptor binding affinity and long-lasting blood pressure-lowering effect." He added, "As guidelines are shifting towards recommending early treatment of hypertension and dyslipidemia and the combination of statin and ezetimibe, active control of blood pressure and LDL cholesterol can help reduce the risk of cardiovascular disease."
Since the launch of Kanarb in 2011, Boryung has been expanding its "Kanarb Family" line of combination products. The company is currently developing a four-drug combination based on Kanarb, as well as combination therapies for hypertension and diabetes.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seong Baekmin, Executive Vice President and Head of BD & Marketing Division at Boryung, stated, "With the launch of Kanavjet, we can offer more diverse treatment options to healthcare professionals and patients." He added, "Based on clinical data from Kanarb, we will strengthen our efforts to target the hypertension and dyslipidemia treatment market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.